| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University of Regensburg |
| Information provided by: | University of Regensburg |
| ClinicalTrials.gov Identifier: | NCT00403884 |
Purpose
In this prospective clinical study SRT is performed with various pulse durations at 1.7µs and additionally 200ns to evaluate the different clinical effects of both laser regimens. The macular diseases to be treated are drusen maculopathy and geographic atrophy due to age-related macular degeneration as well as diabetic macular edema and central serous chorioretinopathy.
The beneficial effect in laser treatment is thought to be associated with the restoration of a new barrier of retinal pigment epithelium cells. If this theory is true, the destruction of the photoreceptors causing visual field defects would be only an unwanted and unnecessary side effect. Thus, SRT is able to avoid these unintentional side effects and to achieve the benefit by just treating the RPE.
In this study the clinical effect of SRT for these diseases is evaluated on a long-term basis.
| Condition | Intervention |
|
Age-Related Macular Degeneration Diabetic Maculopathy Central Serous Chorioretinopathy |
Procedure: Selective RPE laser treatment |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Edema Macular Degeneration |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Selective RPE Laser Treatment (SRT) for Various Macular Diseases |
| Estimated Enrollment: | 60 |
| Study Start Date: | October 2004 |
| Estimated Study Completion Date: | November 2006 |
 |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Carsten Framme, MD | 0049 941 944 9194 | carsten.framme@klinik.uni-regensburg.de |
| Germany | |||||
| University Eye Hospital Regensburg | Recruiting | ||||
| Regensburg, Germany, 93042 | |||||
| Principal Investigator: Carsten Framme, MD | |||||
| Sub-Investigator: Andreas Walter, MD | |||||
| Sub-Investigator: Philipp Prahs, MD | |||||
| University of Regensburg |
| Principal Investigator: | Carsten Framme, MD | University Eye Hospital Regensburg |
More Information
| Study ID Numbers: | University Eye Hospital SRT |
| First Received: | November 24, 2006 |
| Last Updated: | November 24, 2006 |
| ClinicalTrials.gov Identifier: | NCT00403884 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
|
